A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Overview and Strategy XOMA is a biotech royalty aggregator. We have a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Our portfolio was built through the acquisition of rights to future milestones, royalties and commercial payments since our royalty aggregator business model was implemented in 2017. These acquisitions build upon out-licensing agreements for proprietary products and platforms held within our portfolio. Our royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase 1 and 2 development, which we believe have significant commercial sales potential and that are licensed to well-funded partners with established expertise in developing and commercializing drugs.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 9.9M | - | - | - | 37M | 28M |
| Net Income | 22M | -19M | -46M | -23M | 7.8M | 8.8M |
| EPS | $0.75 | $-1.65 | $-4.04 | $-1.98 | $0.65 | $0.78 |
| Free Cash Flow | 0 | -14M | -18M | -13M | 23M | 10M |
| ROIC | 11.1% | -10.2% | -22.3% | -18.2% | 35.7% | 14.0% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 1.24 | 1.44 | 1.40 | 0.13 | 0.17 | 0.24 |
| Dividends/Share | $0.44 | $0.47 | $0.48 | $0.48 | $0.29 | - |
| Operating Income | 1.9M | -40M | -42M | -17M | 18M | 12M |
| Operating Margin | 19.8% | - | - | - | 48.0% | 44.4% |
| ROE | 24.6% | -22.6% | -52.2% | -18.2% | 5.5% | 10.2% |
| Shares Outstanding | 12M | 12M | 11M | 11M | 12M | 11M |
XOMA Royalty Corp passes 0 of 9 quality checks, indicating weak fundamentals.
Total shareholder yield (dividends) is 1.7%. At current prices, the estimated annualized return to fair value is -21.7%.
XOMA Royalty Corp (XOMAO) has a 5-year average return on invested capital (ROIC) of -0.2%. This is below average and may indicate limited pricing power.
XOMA Royalty Corp (XOMAO) has a market capitalization of $315M. It is classified as a small-cap stock.
Yes, XOMA Royalty Corp (XOMAO) pays a dividend with a trailing twelve-month yield of 1.73%. The company also returns capital through share buybacks, with a buyback yield of 0.00%.
XOMA Royalty Corp (XOMAO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
XOMA Royalty Corp (XOMAO) generated $-14 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
XOMA Royalty Corp (XOMAO) has a debt-to-equity ratio of 1.44. This indicates moderate leverage.
XOMA Royalty Corp (XOMAO) reported earnings per share (EPS) of $-1.65 in its most recent fiscal year.
XOMA Royalty Corp (XOMAO) has a return on equity (ROE) of -22.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for XOMA Royalty Corp (XOMAO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
XOMA Royalty Corp (XOMAO) has a book value per share of $7.01, based on its most recent annual SEC filing.
No recent press releases.